CASBF - Week In Review: Shanghai Hansoh Enters $68 Million Deal For Leukemia Candidate
Deals and Financings
Shanghai Hansoh Pharma (HK: 3692) obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment plus milestones of up to $68 million. It will also pay royalties on sales. TRN-000632 is an investigational small molecule allosteric inhibitor of BCR-ABL aimed at treating chronic myeloid leukemia ((CML)). Hansoh already has an approved second-generation BCR-ABL inhibitor for CML, flumatinib, with a different target.
Qilu Pharma of Jinan in-licensed Greater China rights to a treatment for bladder cancer from Seseen Bio of the US in